Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of AZD4547 by measuring the rate of Progression Free Survival at 6 months (PFS6) in recurrent malignant glioma patients with FGFR-TACC fusion. - To characterize the safety and tolerability of AZD4547 in glioma patients - To further assess the anti-tumor activity of AZD4547 for patients with recurrent glioma with FGFR-TACC fusion based on Overall Response Rate for patients with a measurable residue. To assess the efficacy of AZD4547 by measuring the rate of Progression Free Survival at 6 months (PFS6) in recurrent malignant glioma patients with FGFR-TACC fusion. - To characterize the safety and tolerability of AZD4547 in glioma patients - To further assess the anti-tumor activity of AZD4547 for patients with recurrent glioma with FGFR-TACC fusion based on Overall Response Rate for patients with a measurable residue.
Critère d'inclusion
- Recurrent grade III or IV glioma with FGFR3-TACC3 or FGFR1-TACC1 fusion positive by RT-PCR